Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dolutegravir Sodium

FDA-approved product (tablet, oral), marketed as Tivicay, Tivicay Pd.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Dolutegravir Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Integrase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AJ03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dolutegravir Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dolutegravir Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study)

    NCT04901728 · start 2021-07-01

    Registered record
    Registry ID
    NCT04901728
    Conditions
    HIV Infections
    Interventions
    Cultural Domain Analysis; Focus Group Discussion; In-depth interview
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-07-01
    Completion
    2022-07-30
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionCultural Domain Analysis; Focus Group Discussion; In-depth interview
    PhaseNot recorded
    Registry statusUnknown

  • Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI

    NCT04887675 · start 2021-05-01

    Registered record
    Registry ID
    NCT04887675
    Conditions
    HIV I Infection; HIV Associated Lipodystrophy; Metabolic Syndrome; Aging
    Interventions
    MRI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-05-01
    Completion
    2022-10-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV I Infection; HIV Associated Lipodystrophy; Metabolic Syndrome; Aging
    InterventionMRI
    PhaseNot applicable
    Registry statusUnknown

  • Gut Microbiota, PGx and INSTIs Response

    NCT04805944 · start 2021-03-10

    Registered record
    Registry ID
    NCT04805944
    Conditions
    HIV Infections
    Interventions
    Dolutegravir; Bictegravir; Dolutegravir; Dolutegravir; Bictegravir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-03-10
    Completion
    2023-12-31
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDolutegravir; Bictegravir; Dolutegravir; Dolutegravir +1 more
    PhaseNot recorded
    Registry statusCompleted

  • Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil

    NCT04903847 · start 2021-02-02

    Registered record
    Registry ID
    NCT04903847
    Conditions
    Hiv; HIV Infections; HIV Lipodystrophy; Osteoporosis; Renal Insufficiency; Weight Gain; Obesity
    Interventions
    Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]; Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-02-02
    Completion
    2023-02-02
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv; HIV Infections; HIV Lipodystrophy; Osteoporosis +3 more
    InterventionDolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]; Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
    PhasePhase 4
    Registry statusUnknown

  • Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

    NCT04487145 · start 2020-11-23

    Registered record
    Registry ID
    NCT04487145
    Conditions
    Drug-Drug Interaction; HIV Infection
    Interventions
    Dihydroartemisinin-piperaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-11-23
    Completion
    2022-04-11
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-Drug Interaction; HIV Infection
    InterventionDihydroartemisinin-piperaquine
    PhasePhase 4
    Registry statusCompleted

  • Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

    NCT04302896 · start 2020-08-31

    Registered record
    Registry ID
    NCT04302896
    Conditions
    Medication Adherence; HIV
    Interventions
    dolutegravir oral tablet 50mg; emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg; tenofovir disoproxil fumarate oral tablet 300mg; lamivudine oral tablet 300mg
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2020-08-31
    Completion
    2021-09-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedication Adherence; HIV
    Interventiondolutegravir oral tablet 50mg; emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg; tenofovir disoproxil fumarate oral tablet 300mg; lamivudine oral tablet 300mg
    PhaseEarly phase 1
    Registry statusCompleted

  • REal-Life Cohort With DOlutegravir + LAmivudina

    NCT04638686 · start 2020-06-15

    Registered record
    Registry ID
    NCT04638686
    Conditions
    HIV-1-infection
    Interventions
    Dolutegravir 50 MG; Lamivudine 300 MG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-06-15
    Completion
    2022-03-31
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDolutegravir 50 MG; Lamivudine 300 MG
    PhaseNot recorded
    Registry statusCompleted

  • Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone

    NCT04133012 · start 2020-02-10

    Registered record
    Registry ID
    NCT04133012
    Conditions
    HIV-1 Infection
    Interventions
    Samplings
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-02-10
    Completion
    2023-06-09
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionSamplings
    PhaseNot applicable
    Registry statusCompleted

  • Dolutegravir in Real Life in Lesotho

    NCT04238767 · start 2020-02-10

    Registered record
    Registry ID
    NCT04238767
    Conditions
    HIV-1-infection
    Interventions
    Dolutegravir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-02-10
    Completion
    2021-05-20
    Enrolment
    1,433

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDolutegravir
    PhaseNot recorded
    Registry statusCompleted

  • Reducing Antiretroviral Treatments

    NCT04051970 · start 2019-11-27

    Registered record
    Registry ID
    NCT04051970
    Conditions
    HIV-1-infection
    Interventions
    Antiretroviral
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2019-11-27
    Completion
    2022-12-14
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionAntiretroviral
    PhasePhase 3
    Registry statusTerminated

  • Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD

    NCT04050449 · start 2019-10-28

    Registered record
    Registry ID
    NCT04050449
    Conditions
    HIV-1-infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-10-28
    Completion
    2023-03-31
    Enrolment
    1,339

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Nucleosides And Darunavir/Dolutegravir In Africa

    NCT03988452 · start 2019-07-30

    Registered record
    Registry ID
    NCT03988452
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Darunavir; Ritonavir; Dolutegravir; Zidovudine; Tenofovir; Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-07-30
    Completion
    2021-09-30
    Enrolment
    465

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionDarunavir; Ritonavir; Dolutegravir; Zidovudine +2 more
    PhasePhase 3
    Registry statusUnknown

  • Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa

    NCT04066036 · start 2019-05-14

    Registered record
    Registry ID
    NCT04066036
    Conditions
    HIV-1-infection
    Interventions
    This is an observational study only.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-05-14
    Completion
    2023-05-31
    Enrolment
    999

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionThis is an observational study only.
    PhaseNot recorded
    Registry statusCompleted

  • Dolutegravir Pediatric Liquid Formulation Study

    NCT03921723 · start 2019-05-07

    Registered record
    Registry ID
    NCT03921723
    Conditions
    HIV Infections
    Interventions
    Dolutegravir dispersible tablet; Dolutegravir oral suspension; Dolutegravir oral solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-05-07
    Completion
    2019-07-25
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionDolutegravir dispersible tablet; Dolutegravir oral suspension; Dolutegravir oral solution
    PhasePhase 1
    Registry statusCompleted

  • Dolutegravir Plus Lamivudine Simplified Therapy

    NCT03884673 · start 2019-01-01

    Registered record
    Registry ID
    NCT03884673
    Conditions
    HIV/AIDS
    Interventions
    DTG+ 3TC
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2019-01-01
    Completion
    2030-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS
    InterventionDTG+ 3TC
    PhaseNot recorded
    Registry statusRecruiting